Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AURKA | O14965 | 1/20 | 0.36 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.36 |
| ▸ | MTOR | P42345 | 12/20 | 0.35 |
| ▸ | PIK3CA | P42336 | 6/20 | 0.35 |
| ▸ | ATR | Q13535 | 3/20 | 0.35 |
| ▸ | HTR3A | P46098 | 1/20 | 0.34 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.34 |
| ▸ | PIK3R1 | P27986 | 3/20 | 0.33 |
| ▸ | FPR2 | P25090 | 1/20 | 0.31 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.31 |
| ▸ | HTR1A | P08908 | 1/20 | 0.31 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.31 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3059638 | 1.00 | AURKA (0.36) | AURKAPDPK1MTORPIK3CAATR | |
| SCHEMBL2912220 | 0.88 | PIK3CA (0.40) | MTORPIK3CAATRPIK3CDPIK3R1 | |
| SCHEMBL2912224 | 0.88 | PIK3CA (0.40) | MTORPIK3CAATRPIK3CDPIK3R1 | |
| SCHEMBL3066827 | 0.88 | PIK3CA (0.40) | MTORPIK3CAATRPIK3CDPIK3R1 | |
| SCHEMBL2910571 | 0.81 | KDM4E (0.41) | PIK3CAPIK3CD | |
| SCHEMBL2910573 | 0.81 | KDM4E (0.41) | PIK3CAPIK3CD | |
| SCHEMBL2913101 | 0.81 | KDM4E (0.41) | PIK3CAPIK3CD | |
| SCHEMBL13090263 | 0.76 | AURKA (0.41) | AURKAPDPK1MTORPIK3CAATR | |
| Hydrochloric Acid SCHEMBL2904814 | 0.75 | AURKA (0.40) | AURKAPDPK1MTORPIK3CAATR | |
| Hydrochloric Acid SCHEMBL2904817 | 0.75 | AURKA (0.40) | AURKAPDPK1MTORPIK3CAATR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2789338-A2 | Condensed pyridine derivate and use thereof | Takeda Pharmaceutical Company Limited (JP) | 2014-10-15 | — | — | EP | disclosed |
| US-20100266504-A1 | CONDENSED PYRIDINE DERIVATIVE AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-10-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100266504-A1 | CONDENSED PYRIDINE DERIVATIVE AND USE THEREOF | HTR2C, HTR5A, HTR3C | AURKA 4153/4885PDPK1 1501/4885MTOR 1470/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.